The increase is close to inflation and wage growth but much steeper than the atypically small increase in 2022.
© Maksym Yemelyanov stock.adobe.com
The average annual premium for employer-sponsored single and family coverage increased by 7% in 2023, an increase from 2022, but roughly in line with the rate of inflation (5.8%) and wage growth (5.2%), according to the annual KFF Employer Health Benefits Survey.
The survey, which was completed by 2,133 firms, showed that the average annual premium for single coverage was $8,435 and for family coverage, $23,968. Workers, on average, covered 17% of single coverage ($1,401 of $8,435) and 29% of family coverage ($6,575 of $23,968). The average worker contribution for family coverage was considerably higher ($8,334, or 38% of the premium vs. $5,889, or 25%) for workers employed by small firms (3-199 employees) than for those working for large ones (200 or more employee). There wasn’t much difference between small and large firms when it came single coverage, the survey found.
The 7% premium increase is larger than the 2% increase for single coverage in 2022 and the 1% increase in premiums for family coverage. However, 2022 was an outlier because the premiums that year reflected the decrease in utilization of healthcare services in the previous years due to the COVID-19 pandemic
First author Gary Claxton, senior vice president, the director of the Program on the Health Care Marketplace, and his colleagues, noted that increases in health insurance premiums have typically outpaced inflation and wage growth. During the past 10 years, for example, the average family premium has increased by 47% compared with a 30% increase in inflation and 42% increase in wages. But in the past five years, the 22% growth in the average family premium has been closer to the 21% growth in inflation and lower than the 27% increase in wage growth.
This is the 25th year that KFF, formerly known as the Kaiser Family Foundation, has conducted the survey. The response rate to the survey which was fielded from January to July of this year, was 15%, which is similar to the response rate the past two years.
Claxton and his colleagues reported the results of the survey in a Health Affairs article that was published this morning.
Here are some other findings from the survey:
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Roflumilast Foam Showed Strong Results for Scalp and Body Psoriasis in Teens and Adults
May 7th 2025A new JAMA Dermatology study found that once-daily Zoryve (roflumilast) foam, 0.3%, safely and effectively reduced scalp and body plaque psoriasis symptoms in patients 12 and older, offering a convenient, and more tolerated treatment option that may boost adherence and quality of life.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Roflumilast Foam Showed Strong Results for Scalp and Body Psoriasis in Teens and Adults
May 7th 2025A new JAMA Dermatology study found that once-daily Zoryve (roflumilast) foam, 0.3%, safely and effectively reduced scalp and body plaque psoriasis symptoms in patients 12 and older, offering a convenient, and more tolerated treatment option that may boost adherence and quality of life.
Read More
2 Commerce Drive
Cranbury, NJ 08512